Business Context and Reporting Period
Daré Bioscience, Inc. (Nasdaq: DARE) filed a Form 8-K on March 9, 2026, reporting events occurring on March 6, 2026. The company is a Delaware corporation headquartered in San Diego, California.
Key Financial Metrics and Capital Events
The filing details the completion of the second closing of a Regulation A offering. The company issued 17,500 Investor Units at an offering price of $5.00 per unit.
- Units Issued: 17,500 Investor Units
- Components: Each unit consists of one share of Series A Convertible Preferred Stock and two warrants to purchase one share of common stock.
- Warrant Coverage: 35,000 shares of common stock underlying the warrants.
- Gross Proceeds: $87,500 (calculated as 17,500 units × $5.00).
The filing does not provide data on revenue, profit, cash flow, operating margins, debt levels, or liquidity positions.
Material Changes
This filing represents a discrete capital raise event rather than a periodic financial update. There is no prior comparable period data provided within this document to assess material changes in operational metrics.
Guidance, Outlook, and Risks
The offering was conducted pursuant to a Form 1-A offering statement qualified by the SEC on January 5, 2026. The total offering size is up to 4,854,000 units. This filing confirms the partial completion of that offering. The text does not contain management commentary on future guidance, specific risks, contingencies, or unusual items beyond the standard disclosure of the equity sale.
Investor Verification Checklist
- Verify the total number of units sold in the first closing to determine the aggregate capital raised to date against the $24.27 million maximum potential raise (4,854,000 units × $5.00).
- Review the full Form 1-A offering statement (File No. 024-12688) for the use of proceeds and specific terms of the Series A Convertible Preferred Stock.
- Confirm the exercise price and expiration terms of the Investor Warrants issued in this closing.
- Check subsequent filings for the final closing of the Regulation A offering.